Background: The novel coronavirus disease 2019 has become a worldwide threat. We aimed to explore reflections of these unexpected changes to newly diagnosed cancer patients. Method: We searched the 2 months after the index case of our country. The first admission day and the first day of intravenous treatment of newly diagnosed patients were recorded. Results: In the 60 days measured during the pandemic, the total number of patients on polyclinics was 159/weekdays, and the total applied chemotherapy cycles were 276/week. For comparison, the total numbers in the previous year were 267/weekday and 363/week for polyclinic and applied chemotherapy cycles, respectively. The total number of newly admitted patients in 2020 was 283. For comparison, the number of new patients in the same 60-day period in 2019 was 495. Patients who were admitted for adjuvant treatment required a median of 8 days for the first course, those who were admitted for neoadjuvant treatment required 12 days, and metastatic patients required 14 days; there were no significant differences between treatment types (p = 0.233). However, the median treatment time was 11.5 and 17 days, in 2020 and in 2019, respectively. A significant difference was observed between the 2 groups (p < 0.001). Conclusion: The effective shift of workers and accurate regulations have not resulted in apparent delays in patient care. While a decrease in the number of patients has detected, faster healthcare service was introduced to newly diagnosed patients. The reason for the decrease in the number of patients should be investigated with new studies.

1.
ProMED, ISID. Report of Undiagnosed pneumonia – China. [cited 2020 July 9]. Available from: https://promedmail.org/promed-post/?id=6864153
.
2.
WHO. Disease outbreak news. [cited 2020 Jun 29]. Available from: www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
.
3.
Bogoch
II
,
Watts
A
,
Thomas-Bachli
A
,
Huber
C
,
Kraemer
MUG
,
Khan
K
.
Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel
.
J Travel Med
.
2020 Mar 13
(
2
):
27
.
4.
T.C. Ministery of Health. Current Status of Turkey. [cited 2020 July 9]. Available from: https://covid19.saglik.gov.tr/
.
5.
Dai
M
,
Liu
D
,
Liu
M
,
Zhou
F
,
Li
G
,
Chen
Z
, et al.
Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak
.
Cancer Discov
.
2020 Jun
;
10
(
6
):
783
91
. .
6.
Zhang
L
,
Zhu
F
,
Xie
L
,
Wang
C
,
Wang
J
,
Chen
R
, et al.
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
.
Ann Oncol
.
2020 Jul
;
31
(
7
):
894
901
. .
7.
ASCO. ASCO coronavirus resources. [cited 2020 Jun 29]; Available from: https://www.asco.org/asco-coronavirus-information
.
8.
ESMO. ESMO COVID-19 and cancer. [cited 2020 Jun 29]; Available from: https://www.esmo.org/covid-19-and-cancer
.
9.
NCCN. Coronavirus disease 2019 (COVID-19) resources for the cancer care community. [cited 2020 Jun 29]. Available from: https://www.nccn.org/covid-19/
.
10.
Al-Shamsi
HO
,
Alhazzani
W
,
Alhuraiji
A
,
Coomes
EA
,
Chemaly
RF
,
Almuhanna
M
, et al.
A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group
.
Oncologist
.
2020 Jun
;
25
(
6
):
e936
e45
. .
11.
Wang
H
,
Zhang
L
.
Risk of COVID-19 for patients with cancer
.
Lancet Oncol
.
2020 Apr
;
21
(
4
):
e181
. .
12.
Liang
W
,
Guan
W
,
Chen
R
,
Wang
W
,
Li
J
,
Xu
K
, et al.
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
.
Lancet Oncol
.
2020 Mar
;
21
(
3
):
335
7
. .
13.
Moletta
L
,
Pierobon
ES
,
Capovilla
G
,
Costantini
M
,
Salvador
R
,
Merigliano
S
, et al.
International guidelines and recommendations for surgery during Covid-19 pandemic: a systematic review
.
Int J Surg
.
2020 Jul
;
79
:
180
8
. .
14.
Surgery, A.E.G. (2020). Joint Society Statement on Elective Surgery during COVID-19 Pandemic. Published March. [cited 2020 July 9]. Available from: https://www.aagl.org/news/covid-19-joint-statement-on-elective-surgeries
.
15.
Mansfield
SA
,
Abdel-Rasoul
M
,
Terando
AM
,
Agnese
DM
.
Timing of breast cancer surgery-how much does it matter?
Breast J
.
2017 Jul
;
23
(
4
):
444
51
. .
16.
Alkan
A
,
Uncu
A
,
Taşkıran
I
,
Tanrıverdi
Ö
.
Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era
.
Clinics
.
2020
;
75
:
e2033
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.